China SXT Pharmaceuticals, Inc.

NasdaqCM:SXTC Stock Report

Market Cap: US$1.8m

China SXT Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

China SXT Pharmaceuticals's earnings have been declining at an average annual rate of -18.2%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been declining at an average rate of 30% per year.

Key information

-18.2%

Earnings growth rate

33.1%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-30.0%
Return on equity-22.2%
Net Margin-160.7%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

China SXT Pharmaceuticals'(NASDAQ:SXTC) Share Price Is Down 12% Over The Past Year.

Feb 09
China SXT Pharmaceuticals'(NASDAQ:SXTC) Share Price Is Down 12% Over The Past Year.

Revenue & Expenses Breakdown

How China SXT Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:SXTC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 242-330
31 Dec 232-980
30 Sep 232-14140
30 Jun 232-10100
31 Mar 232-660
31 Dec 222-550
30 Sep 223-440
30 Jun 223-550
31 Mar 223-660
31 Dec 212-670
30 Sep 212-770
30 Jun 213-560
31 Mar 215-350
31 Dec 205-540
30 Sep 206-740
30 Jun 205-840
31 Mar 205-1040
31 Dec 196-640
30 Sep 196-240
30 Jun 197030
31 Mar 197230
31 Dec 187130
30 Sep 187130
30 Jun 187120
31 Mar 187120
31 Dec 177110
31 Mar 175110
31 Mar 164010

Quality Earnings: SXTC is currently unprofitable.

Growing Profit Margin: SXTC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SXTC is unprofitable, and losses have increased over the past 5 years at a rate of 18.2% per year.

Accelerating Growth: Unable to compare SXTC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SXTC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Return on Equity

High ROE: SXTC has a negative Return on Equity (-22.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies